167 related articles for article (PubMed ID: 16162013)
1. Bisphosphonate inhibition of the exopolyphosphatase activity of the Trypanosoma brucei soluble vacuolar pyrophosphatase.
Kotsikorou E; Song Y; Chan JM; Faelens S; Tovian Z; Broderick E; Bakalara N; Docampo R; Oldfield E
J Med Chem; 2005 Sep; 48(19):6128-39. PubMed ID: 16162013
[TBL] [Abstract][Full Text] [Related]
2. An investigation of bisphosphonate inhibition of a vacuolar proton-pumping pyrophosphatase.
Szabo CM; Oldfield E
Biochem Biophys Res Commun; 2001 Sep; 287(2):468-73. PubMed ID: 11554752
[TBL] [Abstract][Full Text] [Related]
3. 3-D QSAR investigations of the inhibition of Leishmania major farnesyl pyrophosphate synthase by bisphosphonates.
Sanders JM; Gómez AO; Mao J; Meints GA; Van Brussel EM; Burzynska A; Kafarski P; González-Pacanowska D; Oldfield E
J Med Chem; 2003 Nov; 46(24):5171-83. PubMed ID: 14613320
[TBL] [Abstract][Full Text] [Related]
4. In Vitro and In Vivo Investigation of the Inhibition of Trypanosoma brucei Cell Growth by Lipophilic Bisphosphonates.
Yang G; Zhu W; Kim K; Byun SY; Choi G; Wang K; Cha JS; Cho HS; Oldfield E; No JH
Antimicrob Agents Chemother; 2015 Dec; 59(12):7530-9. PubMed ID: 26392508
[TBL] [Abstract][Full Text] [Related]
5. Bisphosphonate inhibitors of Toxoplasma gondi growth: in vitro, QSAR, and in vivo investigations.
Ling Y; Sahota G; Odeh S; Chan JM; Araujo FG; Moreno SN; Oldfield E
J Med Chem; 2005 May; 48(9):3130-40. PubMed ID: 15857119
[TBL] [Abstract][Full Text] [Related]
6. Novel inhibitors of the trypanosome alternative oxidase inhibit Trypanosoma brucei brucei growth and respiration.
Ott R; Chibale K; Anderson S; Chipeleme A; Chaudhuri M; Guerrah A; Colowick N; Hill GC
Acta Trop; 2006 Dec; 100(3):172-84. PubMed ID: 17126803
[TBL] [Abstract][Full Text] [Related]
7. Bisphosphonate inhibition of phosphoglycerate kinase: quantitative structure-activity relationship and pharmacophore modeling investigation.
Kotsikorou E; Sahota G; Oldfield E
J Med Chem; 2006 Nov; 49(23):6692-703. PubMed ID: 17154500
[TBL] [Abstract][Full Text] [Related]
8. Quantitative structure-activity relationships for gammadelta T cell activation by bisphosphonates.
Sanders JM; Ghosh S; Chan JM; Meints G; Wang H; Raker AM; Song Y; Colantino A; Burzynska A; Kafarski P; Morita CT; Oldfield E
J Med Chem; 2004 Jan; 47(2):375-84. PubMed ID: 14711309
[TBL] [Abstract][Full Text] [Related]
9. Trypanosoma brucei: effects of methoprene and other isoprenoid compounds on procyclic and bloodstream forms in vitro and in mice.
Harmon MA; Scott TC; Li Y; Boehm MF; Phillips MA; Mangelsdorf DJ
Exp Parasitol; 1997 Nov; 87(3):229-36. PubMed ID: 9371088
[TBL] [Abstract][Full Text] [Related]
10. Trypanocidal activity of piperazine-linked bisbenzamidines and bisbenzamidoxime, an orally active prodrug.
Huang TL; Bacchi CJ; Kode NR; Zhang Q; Wang G; Yartlet N; Rattendi D; Londono I; Mazumder L; Vanden Eynde JJ; Mayence A; Donkor IO
Int J Antimicrob Agents; 2007 Dec; 30(6):555-61. PubMed ID: 17920820
[TBL] [Abstract][Full Text] [Related]
11. Quantitative structure-activity relationships for a series of inhibitors of cruzain from Trypanosoma cruzi: molecular modeling, CoMFA and CoMSIA studies.
Trossini GH; Guido RV; Oliva G; Ferreira EI; Andricopulo AD
J Mol Graph Model; 2009 Aug; 28(1):3-11. PubMed ID: 19376735
[TBL] [Abstract][Full Text] [Related]
12. Activity of sulfonium bisphosphonates on tumor cell lines.
Zhang Y; Hudock MP; Krysiak K; Cao R; Bergan K; Yin F; Leon A; Oldfield E
J Med Chem; 2007 Nov; 50(24):6067-79. PubMed ID: 17963374
[TBL] [Abstract][Full Text] [Related]
13. Parasite-based screening and proteome profiling reveal orlistat, an FDA-approved drug, as a potential anti Trypanosoma brucei agent.
Yang PY; Wang M; Liu K; Ngai MH; Sheriff O; Lear MJ; Sze SK; He CY; Yao SQ
Chemistry; 2012 Jul; 18(27):8403-13. PubMed ID: 22674877
[TBL] [Abstract][Full Text] [Related]
14. In vitro trypanocidal activity of the anti-helminthic drug niclosamide.
Merschjohann K; Steverding D
Exp Parasitol; 2008 Apr; 118(4):637-40. PubMed ID: 18226810
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of Trypanosoma cruzi hexokinase by bisphosphonates.
Hudock MP; Sanz-Rodríguez CE; Song Y; Chan JM; Zhang Y; Odeh S; Kosztowski T; Leon-Rossell A; Concepción JL; Yardley V; Croft SL; Urbina JA; Oldfield E
J Med Chem; 2006 Jan; 49(1):215-23. PubMed ID: 16392806
[TBL] [Abstract][Full Text] [Related]
16. Activity of bisphosphonates against Trypanosoma brucei rhodesiense.
Martin MB; Sanders JM; Kendrick H; de Luca-Fradley K; Lewis JC; Grimley JS; Van Brussel EM; Olsen JR; Meints GA; Burzynska A; Kafarski P; Croft SL; Oldfield E
J Med Chem; 2002 Jul; 45(14):2904-14. PubMed ID: 12086478
[TBL] [Abstract][Full Text] [Related]
17. DNA binding affinity of bisguanidine and bis(2-aminoimidazoline) derivatives with in vivo antitrypanosomal activity.
Dardonville C; Barrett MP; Brun R; Kaiser M; Tanious F; Wilson WD
J Med Chem; 2006 Jun; 49(12):3748-52. PubMed ID: 16759117
[TBL] [Abstract][Full Text] [Related]
18. Cysteine proteinase inhibitors kill cultured bloodstream forms of Trypanosoma brucei brucei.
Troeberg L; Morty RE; Pike RN; Lonsdale-Eccles JD; Palmer JT; McKerrow JH; Coetzer TH
Exp Parasitol; 1999 Apr; 91(4):349-55. PubMed ID: 10092479
[TBL] [Abstract][Full Text] [Related]
19. Design and synthesis of peptidomimetic protein farnesyltransferase inhibitors as anti-Trypanosoma brucei agents.
Ohkanda J; Buckner FS; Lockman JW; Yokoyama K; Carrico D; Eastman R; de Luca-Fradley K; Davies W; Croft SL; Van Voorhis WC; Gelb MH; Sebti SM; Hamilton AD
J Med Chem; 2004 Jan; 47(2):432-45. PubMed ID: 14711313
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis, and structure-activity relationship of Trypanosoma brucei leucyl-tRNA synthetase inhibitors as antitrypanosomal agents.
Ding D; Meng Q; Gao G; Zhao Y; Wang Q; Nare B; Jacobs R; Rock F; Alley MR; Plattner JJ; Chen G; Li D; Zhou H
J Med Chem; 2011 Mar; 54(5):1276-87. PubMed ID: 21322634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
